This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

CVS Caremark Research Finds New, More Accurate Method For Classifying Patient Medication Adherence Behaviors

Stocks in this article: CVS

WOONSOCKET, R.I., Sept. 12, 2013 /PRNewswire/ -- Researchers at CVS Caremark (NYSE:CVS) and Brigham and Women's Hospital have found that a new approach to classifying patients by their long-term medication adherence behavior may be more accurate than traditional approaches. In a study published in the September 2013 issue of Medical Care, the researchers followed more than 264,000 statin-users over a 15-month period and created measures to account for different adherence behaviors. The researchers identified key groups into which various patients would fall based on these measures in an effort to predict and compare their long-term adherence patterns.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO )

The study utilized a new method of categorizing adherence called group-based trajectory modeling, which is based upon observed patterns of medication-filling over time.  This method allows researchers to more accurately capture and describe adherence compared to techniques that simply classify patients as adherent or not, using average levels of adherence.  In addition, the trajectory patterns that are created should allow for more targeted interventions to address non-adherence.  In this study, use of trajectory modeling was especially useful for accounting for variable patterns of intermittent and long-term adherence behaviors.

"Our findings could help facilitate research on medication adherence and medication effectiveness in a variety of ways," said Niteesh Choudhry, MD, PhD, associate physician, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and associate professor, Harvard Medical School. "For example, by using group-based trajectory modeling, we could help identify patients with distinct patterns of adherence so that health care professionals could appropriately target interventions.  In addition, data related to the quantity and timing of medication availability could help improve our understanding of the effects of nonadherence on clinical outcomes."

Based on the study group, researchers categorized patients into six distinct groups according to characteristics:

  • Nearly always adherent (23.4 percent)
  • Brief gap in medication use or filled irregularly during the first nine months, but improved during the last six months (11.4 percent)
  • Slowly declining adherence throughout the 15 month period (11.3 percent)
  • Used statins only occasionally across the 15 month study period (15.0 percent)
  • Rapid decline in statin use after initiation (19.3 percent)
  • Virtually no fills after their initial fill (23.4 percent)

Group trajectory modeling also identified certain characteristics that impact medication adherence.  For example, among the study participants, on average, those patients with the best adherence were older, more likely to have a higher income, more likely to be a high school graduate and less likely to be black. In addition, those with the best adherence were more likely to be a Medicare Part D beneficiary or live in New England. Those with the lowest adherence rates tended to be generally younger, male and less likely to have an initial prescription that provided them with more than a 30-day supply of medication.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,788.61 +69.61 0.39%
S&P 500 2,061.96 +9.21 0.45%
NASDAQ 4,715.2680 +13.4010 0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs